Capecitabine increases disease-free survival for HER2-negative breast cancer patients

[News]

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12.

More... (http://www.news-medical.net/news/20151211/Capecitabine-increases-disease-free-survival-for-HER2-negative-breast-cancer-patients.aspx)